Treating COVID-19 with colchicine in community healthcare setting

Clin Immunol. 2020 Aug:217:108490. doi: 10.1016/j.clim.2020.108490. Epub 2020 May 31.
No abstract available

Keywords: COVID-19; Colchicine; Community; Inflammation; SARS-CoV-2.

Publication types

  • Letter

MeSH terms

  • Acetaminophen / therapeutic use
  • Anti-Inflammatory Agents / therapeutic use*
  • Azithromycin / therapeutic use
  • Betacoronavirus / drug effects
  • Betacoronavirus / immunology
  • Betacoronavirus / pathogenicity
  • COVID-19
  • Cohort Studies
  • Colchicine / therapeutic use*
  • Community Health Services
  • Coronavirus Infections / drug therapy*
  • Coronavirus Infections / immunology
  • Coronavirus Infections / virology
  • Cytokine Release Syndrome / immunology
  • Cytokine Release Syndrome / prevention & control*
  • Cytokine Release Syndrome / virology
  • Fever / drug therapy*
  • Fever / immunology
  • Fever / virology
  • Gene Expression
  • Humans
  • Immunity, Innate / drug effects
  • Inflammasomes / antagonists & inhibitors
  • Inflammasomes / genetics
  • Inflammasomes / immunology
  • Intensive Care Units
  • Interleukin-1 / antagonists & inhibitors
  • Interleukin-1 / genetics
  • Interleukin-1 / immunology
  • Interleukin-6 / antagonists & inhibitors
  • Interleukin-6 / genetics
  • Interleukin-6 / immunology
  • Italy
  • Pandemics
  • Pneumonia, Viral / drug therapy*
  • Pneumonia, Viral / immunology
  • Pneumonia, Viral / virology
  • SARS-CoV-2
  • Severe Acute Respiratory Syndrome / immunology
  • Severe Acute Respiratory Syndrome / prevention & control*
  • Severe Acute Respiratory Syndrome / virology
  • Time Factors

Substances

  • Anti-Inflammatory Agents
  • IL6 protein, human
  • Inflammasomes
  • Interleukin-1
  • Interleukin-6
  • Acetaminophen
  • Azithromycin
  • Colchicine